Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Benzinga.com  October 24, 2018

REVLIMID® (lenalidomide) Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma

Business Wire October 23, 2018

Celgene Corporation Announces Appointment of Dr. Alise Reicin to President, Global Clinical Development

Business Wire October 22, 2018

First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018

Business Wire October 22, 2018

The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Benzinga.com  October 21, 2018

Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy

Business Wire October 11, 2018

New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018

Business Wire October 10, 2018

Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint

Business Wire October 8, 2018

Celgene Corporation to Announce Third Quarter 2018 Results on October 25, 2018

Business Wire October 1, 2018

S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion

PR Newswire September 24, 2018

OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone

Business Wire September 12, 2018

Thinking about buying stock in American Tower, Alibaba, Celgene, Callaway Golf Co. or Marathon Petroleum Corp.?

PR Newswire September 11, 2018

Celgene Corporation to Webcast at Upcoming Investor Conferences

Business Wire August 23, 2018

Celgene Reports Second Quarter 2018 Operating and Financial Results

Business Wire July 26, 2018

Celgene Announces Phase III ‘AUGMENT’ Study of REVLIMID® in Combination with Rituximab (R2) for the Treatment of Patients with Relapsed/Refractory Indolent Lymphoma Met Primary Endpoint

Business Wire July 23, 2018

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Business Wire July 10, 2018

Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Business Wire July 9, 2018

Celgene Corporation to Announce Second Quarter 2018 Results on July 26, 2018

Business Wire July 2, 2018

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

Business Wire June 28, 2018

Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi

Business Wire June 19, 2018